Chronic inflammatory demyelinating polyradiculoneuropathy research hub
4 indexed studies · 4 currently recruiting
- recruitingTherapeutic exploratory (Phase II)
A Phase 2, multicenter, open-label, non-randomized, proof-of-concept study evaluating the efficacy, safety, and tolerability of SAR445088 in adults with chronic inflammatory demyelinating polyneuropathy (CIDP)
This study is testing a new medicine, riliprubart (also called SAR445088), for adults with a nerve condition called CIDP. Researchers want to see if it's safe and helps improve symptoms or stop them from coming back, especially in people who haven't responded well to usual treatments.
Poland · Germany · France - recruitingPHASE3
A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP
This study is testing a new medicine called empasiprubart for adults with a nerve condition called CIDP. It wants to see if the medicine is safe and helps people feel better. Participants will get the study medicine or a dummy medicine first, then everyone will get the study medicine.
United States · Argentina · Austria - recruitingPHASE3
A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not Work
This study is testing a new medicine, riliprubart, for people with a long-term nerve condition called CIDP. It's for those who haven't improved with usual treatments. We want to see if riliprubart is safe and helps improve symptoms compared to a dummy medicine.
United States · Argentina · Belgium - recruiting
Real-World Efgartigimod Effectiveness in CIDP: A Prospective Study
This study looks at how a treatment called efgartigimod works for people in the UK with a nerve condition called CIDP. It aims to understand patients' experiences, how they use healthcare, and if the treatment is effective in real life.
United States · Germany